Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Cardio Diagnostics Holdings's OCF Margin % or its related term are showing as below:
CDIO'
s OCF Margin % Range Over the Past 10 Years
Min: -509100 Med: -38180 Max: -14265.71
Current: -34635.29
During the past 6 years, the highest OCF Margin % of Cardio Diagnostics Holdings was -14265.71%. The lowest was -509100.00%. And the median was -38180.00%.
CDIO's OCF Margin % is ranked worse than 96.85% of 952
companies
in the Biotechnology industry
Industry Median: -68.59
vs CDIO: -34635.29
Cardio Diagnostics Holdings OCF Margin % Related Terms
Cardio Diagnostics Holdings OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardio Diagnostics Holdings's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardio Diagnostics Holdings OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Cardio Diagnostics Holdings's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardio Diagnostics Holdings (CDIO) has a OCF Margin % of -52,066.67% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cardio Diagnostics Holdings and its competitors. According to the industry distribution chart, Cardio Diagnostics Holdings ranks #922 out of 952 companies in the Biotechnology industry, placing it in the top 96.8%.
Is Cardio Diagnostics Holdings' OCF Margin % too high?
Cardio Diagnostics Holdings' current OCF Margin % is -52,066.67%. Based on the distribution chart, Cardio Diagnostics Holdings ranks #922 out of 952 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cardio Diagnostics Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardio Diagnostics Holdings' OCF Margin % compare to ERNA and LABT?
According to the Biotechnology industry distribution chart, Cardio Diagnostics Holdings ranks #922 out of 952 companies for OCF Margin %. This places Cardio Diagnostics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cardio Diagnostics Holdings and its competitors. Cardio Diagnostics Holdings's current OCF Margin % is -52,066.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardio Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings (CDIO) is currently considered Possible Value Trap. The stock's GF Value™ is $2.77, compared to a current price of $1.57 — trading 43.3% below its estimated fair value. The current OCF Margin % is -52,066.67%. Cardio Diagnostics Holdings' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Cardio Diagnostics Holdings (CDIO), the current OCF Margin % is -52,066.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be undervalued.
The current stock price of $1.57 is trading 43.3% below its estimated GF Value™ of $2.77.
GuruFocus considers Cardio Diagnostics Holdings to be Possible Value Trap.
Key valuation signals for CDIO:
OCF Margin %: -52,066.67%
GF Value™: $2.77 vs. price of $1.57 (43.3% below fair value)
No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
49GF Score
Get the complete analysis for CDIO
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIO has been successfully added to your 
